Sig Brokerage LP purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 1,064 shares of the biopharmaceutical company's stock, valued at approximately $758,000.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Rakuten Securities Inc. raised its holdings in Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 15 shares during the last quarter. OFI Invest Asset Management bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth about $28,000. Avalon Trust Co bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth about $36,000. Crowley Wealth Management Inc. bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth about $36,000. Finally, Private Wealth Management Group LLC raised its holdings in Regeneron Pharmaceuticals by 260.0% during the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 39 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.
Regeneron Pharmaceuticals Stock Up 0.4%
Shares of NASDAQ REGN traded up $2.22 during trading hours on Monday, hitting $596.54. The company had a trading volume of 666,223 shares, compared to its average volume of 789,443. The stock has a market capitalization of $64.41 billion, a P/E ratio of 15.58, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1-year low of $520.50 and a 1-year high of $1,211.20. The firm's 50 day moving average is $599.96 and its 200-day moving average is $681.90.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. During the same quarter last year, the company posted $9.55 EPS. The firm's revenue was down 3.7% on a year-over-year basis. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.
Regeneron Pharmaceuticals Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.59%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.
Wall Street Analyst Weigh In
REGN has been the subject of several recent research reports. StockNews.com cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. Bank of America lowered their price target on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research note on Thursday, April 17th. TD Cowen lowered their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a research note on Tuesday, February 4th. BMO Capital Markets lowered their price target on Regeneron Pharmaceuticals from $865.00 to $800.00 and set an "outperform" rating for the company in a research note on Wednesday, April 30th. Finally, Royal Bank of Canada lowered their price target on Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an "outperform" rating for the company in a research note on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $890.60.
View Our Latest Analysis on REGN
About Regeneron Pharmaceuticals
(
Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Further Reading
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
